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Abstract 
Purpose: pentoxifylline (PTX) and tocopherol (vitamin E) are antioxidants previously shown to be useful in combination in the treatment 
of late radiation induced toxicity. The purpose of this study was to investigate the benefit of combination therapy with carbogen 
pentoxifylline and tocopherol in the mitigation of late radiation effects. As the optimal duration of PTX and tocopherol treatment has not 
been fully established, we studied short versus extended treatment duration.   
Methods: we conducted a phase II prospective randomized study of short versus prolonged treatment with pentoxifylline (800 mg) and 
tocopherol (1000 IU) orally once daily in patients with grade three toxicity post-radical radiotherapy. In addition, all 18 patients received 
inhaled carbogen (95% O + 5% CO2) over 90 minutes, five days/week, for three weeks. The primary end point was improved in 
maximum Lent-Soma toxicity scores. 
Results: maximum Lent-Soma scores improved in six of the 18 patients (response rate 33%). The proportion of patients responding to 
treatment in the prolonged treatment arm B was more than double than in the shorter arm A, but this did not reach statistical significance 
(p=0.321). Two patients who had prolonged treatment (arm B) had complete resolution of their symptoms, which was maintained at two 
and three year follow-ups. 
Conclusions: we recommend prolonged treatment for 12 months, with PTX and tocopherol in combination with carbogen therapy, in the 
management of late radiation effects. 
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Introduction 
As cancer treatment outcomes improve, there is increased 
emphasis on reducing toxicity of treatment as part of an effort to 
broaden the therapeutic index of therapy. Late radiotherapy 
effects are a considerable source of symptomatic morbidity in 
survivors of cancer therapy. Although traditionally considered 
progressive and irreversible, there is now mounting evidence to 
support the potential reversibility and treatment of 
radiotherapeutic injury using antioxidant therapy [1,2].  
Over the past decade, there have been several reports in 
support of tocopherol and pentoxifylline (PTX) in the treatment 
of late radiation effects [1,2,3]. Hyperbaric oxygen has also 
shown some efficacy in this area [4]. Carbogen is thought to act 
similarly to hyperbaric oxygen (HBO) by reversing tissue 
hypoxia and thus removing free radicals, which are implicated in 
the pathogenesis of late radiation effects [5]. 
The combination of PTX and tocopherol has yielded far greater 
and consistent results than the use of either agent alone [1]. We 
postulated that the addition of carbogen therapy to this 
combination would further enhance the modulation of radiation-
induced normal tissue damage. The optimum duration of 
treatment has not been fully established, with trials continuing 
treatment for a variety of times from three to 36 months [2]. 
We conducted a phase II prospective randomized study, 
examining the benefit of extended compared to short-term use 
of PTX and tocopherol used in combination with carbogen 




The study design involved a prospective, randomized trial of 
short versus prolonged treatment, with pentoxifylline and 
tocopherol in addition to inhaled carbogen (95% O + 5% CO2). 
Carbogen was inhaled via a close-fitting face mask, with a one-
way valve and closed breathing system over 90 minutes/day, 
five days/week, for three weeks. Patients were randomized to 
either arm A, which consisted of a short three-week course of 
pentoxifylline and tocopherol, or arm B, which was a prolonged 
12-month course. Pentoxifylline was administered at a dose of 
800 mg and tocopherol at a dose of 1000 IU. Both were taken 
orally once daily, and the same dose was used in both arms of 
the study. 
Patients with grade 3 (Lent-Soma) [6] toxicity, post-radical 
radiotherapy, for a variety of cancer primaries, were eligible for 
the trial. Inclusion criteria required that patients had received 
radical radiotherapy that consequently caused grade 3 side 
effects within the irradiated area. Patients were accrued as a 
consecutive presenting sample. Eighteen patients with 
significant late morbidity post-radical radiation therapy were 
randomized to one of the two study arms, using envelope 
randomization (see Figure 1). 
Figure 1 depicts the randomization process. All 18 patients in 
the study received carbogen therapy (95% O + 5% CO2) over 
90 minutes, five days/week, for three weeks, which was inhaled 
via a close-fitting face mask, with a one-way valve and closed 
breathing system, over 90 minutes daily five days/week, for 
three weeks. Patients were randomized to either arm A, which 
consisted of a short three-week course of pentoxifylline and 
tocopherol, or arm B, which was a prolonged 12-month course. 
Pentoxifylline was administered at a dose of 800 mg and 
tocopherol at a dose of 1000 IU. Both were taken orally once 
daily, and the same dose was used in both arms of the study. 
We initially planned to include 30 patients in the trial. However, 
due to slow accrual the study was closed after 18 patients. One 
of the reasons for slow accrual was patients' reluctance to 
attend the hospital day ward 15 times over a three-week period 
for carbogen therapy. The study commenced in March 2001 
and randomization completed in August 2003. The mean time 
period between completion of radiotherapy and study enrolment 
was 58.6 months (range 11–224 months). Of the 18 patients, 
three were male and 15 were female. The mean age was 59.9 
years (range 22–82 years). The group included eight patients 
with breast cancer, four patients with head and neck cancer, 
four patients with gynaecological malignancies, one patient with 
gastro-intestinal malignancy and one case of Bowen’s disease 
of the skin. Radiation-induced toxicities included subcutaneous 
fibrosis lymphoedema, post-radiation cystitis and increased 
bowel frequency (see Table 1). 
The severity of radiation late effects was assessed using the 
Lent-Soma (late effect normal tissues subjective objective 
management and analytic) scale, defined by the Radiation 
Therapy Oncology Group and the European Organisation for 
the Research and Treatment of Cancer [6]. Clinical assessment 
of late side effects, recorded using Lent-Soma scales, was used 
as the primary end point. Maximum Lent-Soma scores were 
recorded at baseline and at four, eight and 12 months post-
treatment. One patient did not receive any treatment as she was 























Figure 1: The randomization process
 
hospitalized for treatment of an infection. Intention to treat 
analysis was performed. Patient’s data were entered onto 
EXCEL and transferred to Minitab statistical software for 
statistical analysis. We compared the overall proportions of 
responders in each arm of the trial, using Fisher's exact test 
with a significance level of p=0.05. 
Written information consent was obtained from all patients. 
Ethical approval was obtained from St Lukes Ethics and Medical 
Research Committee. 
Results 
All patients tolerated carbogen therapy extremely well. Three 
patients experienced nausea due to pentoxifylline, one of whom 
discontinued treatment. The other two patients improved on 
commencing domperidone medication. We subsequently 
adopted a policy of administering five days of domperidone to 
all patients routinely at the start of therapy. Following this there 
were no further reports of nausea. 
Of the 17 patients who received treatment, six patients had 
improvement in their symptoms (see Tables 1 and 2), thus



















Table 1: Overall results 
 



















Table 2: Proportion of patients responding to treatment according to diagnosis and treatment arm 
 
 
Table 3: Results of Fisher's exact test for comparison of proportions responding in each arm, using frequencies in frequency 
 
 
giving an overall response rate of 33%. The overall proportions 
responding in each arm were 2/10 in arm A versus 4/8 in arm B. 
Although the proportion responding to treatment in the 
prolonged treatment arm B was more than double (0.5 versus 
0.2) than in the shorter arm A, (see Table 3) the difference is 
not statistically significant (p=0.321). 
The median time to onset of response was 3.5 months with a 
range of 2–7 months (see Table 1). Of the two patients in the 
shorter treatment group A arm who responded, the first (patient 
5) had dysuria and diarrhoea, which showed an initial 
improvement from grade 3 to grade 2 after two months, but her 
symptoms subsequently recurred. She was later re-treated with 
15 sessions of carbogen over a three-week period, and 12 
months of pentoxifylline (800 mg) and tocopherol (1000 IU). On 
re-treatment, with the extended regimen, her dysuria reduced to 
grade 1 and this benefit was maintained for over one year. The 
second patient (patient 14) had fibrosis post-breast 
radiotherapy, which improved from grade 3 to grade 2 toxicity at 
two months, but then subsequently refused further follow-up for 
personal reasons. 
Four of the eight patients in the prolonged 12-month treatment 
arm B demonstrated response to treatment. Two of these 
patients with grade 3 fibrosis (patients 17 and 18 in Table 1) 
had complete resolution of their symptoms, and this benefit was 
maintained for two and three years, respectively. The third 
patient (patient 6) had urinary incontinence, which improved 
from grade 3 to grade 2 toxicity, and this was maintained for 
one year. The final patient (patient 4) had dysuria and PV 
bleeding, which improved from grade 3 to grade 2, but this 
benefit was not maintained. 
 
Discussion
Late radiation effects are progressive in nature and have a 
significant negative impact on quality of life in long-term cancer 
survivors. In our study, 33% of patients had an improvement in 
their symptoms, which otherwise would have remained 
unchanged or perhaps even worsened. We feel that the 
combination of carbogen with PTX and tocopherol represents 
an effective treatment, especially as treatment was well 
tolerated, cost-effective and no established alternative currently 
exists. Although nausea was a side effect of the PTX treatment, 
this responded well to treatment with domperidone. 
Late radiotherapy effects are a debilitating, chronic, adverse 
effect of treatment and have traditionally been considered both 
progressive and irreversible. In such circumstances, prevention 



















is often the best cure and limiting both dose and volume to 
irradiated tissues is imperative in reducing the incidence and 
extent of such effects. Despite these efforts, there is much 
individual variation and unpredictability in regard to 
development of late radiotherapy side effects. Treatment 
intensification is becoming increasingly popular both in terms of 
concurrent chemotherapy and intensified fractionation schemes. 
However, this will likely be at the expense of increased 
incidence and severity of late radiotherapeutic injury. 
The irreversibility of late radiation effects has been disputed for 
some time [1,2]. Radiation induced injury is traditionally thought 
to be a chronic progressive process due to mitotic cell death in 
tissues and reduction in the number of surviving clonogens. 
However, in recent times, there is increasing evidence to 
suggest that this process is not entirely irreversible [3], and that 
late radiation effects are due to a much more dynamic 
interactive process between multiple cell types, including 
parenchymal and vascular cells. This is enhanced by secretion 
of a cascade of pro-inflammatory and fibrogenic cytokines [7].  
As an anticytokine pentoxifylline is thought to reverse this 
process [8]. PTX is a haemorheologic methylxanthine derivative 
initially developed to improve blood viscosity and 
microcirculatory disorders. Alpha tocopherol is a powerful 
antioxidant that protects membrane phospholipids from 
oxidative damage [9] and acts as a scavenger of reactive 
oxygen species. The precise mechanism of action of these 
agents is not yet known. Both PTX and tocopherol are 
antioxidants previously shown to be of superior benefit in 
combination in the treatment of late radiation effects [3]. In a 
clinical trial, Delanian et al reported objective response rates of 
53% at six months, using this combination [10], that is 
regression of radiation-induced fibrosis surface area. Our study 
reports a response rate of 33%, giving further confirmation of 
the efficacy of this combination in the treatment of late 
radiotherapy effects. 
Hyperbaric oxygen therapy (HBOT) has been used to treat 
several medical conditions, including necrotising fasciitis and 
osteoradionecrosis [11]. It has been used in radiation oncology, 
as both a radiosensitiser and also as a treatment of late 
radiation effects. It is thought to stimulate angiogenesis and 
improve tissue oxygenation, resulting in healing of damaged 
soft tissue bone and cartilage. In a small placebo controlled 
prospective trial, Carl et al reported significant improvements in 
pain and swelling in 44 patients with late radiation induced injury 
post-radiotherapy for breast cancer [4]. In another retrospective 
trial of 75 patients with osteoradionecrosis, 81% of patients 
responded to HBOT [12]. The Consensus Conference, led by 
the European Society for Therapeutic Radiology and Oncology 
and the European Committee for Hyperbaric Medicine, 
recommended prospective collection of toxicity data and setting 
up of multi-centre randomized controlled trials to obtain higher 
levels of evidence for indications of HBOT [11]. 
Carbogen is thought to work in a similar manner to HBOT. In a 
study by Collet et al, there was no difference in results between 
hyperbaric oxygen and slightly pressurized air, and the two 
treatments were considered equally effective [13]. Powel et al 
conducted a study that showed breathing carbogen (5% CO2 
and 95% O) increased tumour oxygenation, by comparing pO2 
measurements pre- and post-carbogen breathing [5]. In our 
study, carbogen therapy was tolerated well. As patients were 
not randomized for carbogen therapy, it is not possible to 
assess the relative contribution of carbogen to the results 
obtained. 
The optimum duration of treatment has not been fully 
established, with other trials continuing treatment for various 
durations from three to 36 months [2]. This trial showed a trend 
towards better response with more prolonged treatment, with 
three of the four patients in the prolonged treatment arm B, 
maintaining their improvements for 1–3 years. Also, the 
proportion responding to treatment in the prolonged treatment 
arm B was more than double that in the shorter arm A. This 
result was not statistically significant, possibly due to the small 
number of patients in the study and also the combination of 
patients with a variety of late toxicities in this study. However, 
this finding is consistent with other studies [2] and gives further 
confirmation of the benefit of prolonged treatment. We 
recommend clinical use of these agents with treatment duration 
of at least 12 months. 
In addition, there is evidence for rebound effects in this study if 
the treatment period is too short. One patient had a recurrence 
of her symptoms on completion of the shorter three-week 
course, suggesting a rebound effect. In a study of response 
kinetics in long-term treatment with PTX and tocopherol, 
Delanian  et al also reported a rebound effect due to 
discontinuation of treatment in three of seven patients in the 
shorter treatment arm [2]. The same patient in our trial had an 
even more substantial improvement from grade 3 to grade 1 
toxicity (diarrhoea) on re-treatment with this therapy for 12 
months, thus giving further basis for more prolonged therapy. 
This was a heterogeneous group of patients indicating the 
broad scope of potential benefit with this treatment. Other 
groups have reported improvement in 71% of patients with 
proctitis and enteritis with combination PTX and tocopherol 
therapy [14]. Gothard et al have shown significant 



















improvements in Lent-Soma scores for genito-urinary 
dysfunction and proctitis with this combination [15]. This 
combination has also been studied in osteoradionecrosis [16], 
and pentoxifylline has been shown to be of benefit in radiation-
induced trismus [17] and lung toxicity in patients with breast and 
lung cancer [18]. 
However, several studies have examined the use of PTX and 
tocopherol specifically in the management of radiation-induced 
subcutaneous fibrosis [1,2 and 11]. We would support this as, in 
our study, two patients with radiation-induced fibrosis both had 
complete resolution of their symptoms on the prolonged 
treatment arm B. These improvements were maintained for two 
and three years, respectively, and thus they represent the most 
significant responses in our trial. There has been much 
progress in understanding the molecular mechanisms and 
pathophysiology involved in radiation injury, and this should be 
used to model therapeutic strategies for this disease. In the era 
of targeted therapies, agents such as angiotensin-converting 
enzyme (ACE) inhibitors and angiotensin receptor type I 
antagonists, which target the renin-angiotensin system, are 
proving to be of benefit in modulating late radiation effects in
kidney and lung tissues [19]. These tissues are known to 
possess an intrinsic renin-angiotensin system. ACE inhibitors 
are also being studied in radiation-induced lung injury in the 
RTOG 0123 study [20]. Thus, it may be possible to direct the 
use of different aetiology-based treatments to tissue-specific 
late radiation reactions. In this instance, we would suggest that 
combination therapy with carbogen PTX and tocopherol might 
be of greater benefit in the management of radiation-induced 
subcutaneous fibrosis. Future studies with this therapeutic 
combination should involve sub-group analysis for late radiation 
effects in different tissue types, as perhaps not all radiation-
induced toxicity will respond in a similar manner. 
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